Ibuzatrelvir
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Ibuzatrelvir
- Molecular weight
- 489.5
- Structure (SMILES)
- COC(=O)N[C@H](C(=O)N1C[C@H](C(F)(F)F)C[C@H]1C(=O)N[C@H](C#N)C[C@@H]1CCNC1=O)C(C)(C)C
- drug pf 07817883
- Drug: PF-07817883
- ibuzatrelvir
- Ibuzatrelvir
- ibuzatrelvir [INN]
- IBUZATRELVIR [USAN]
- Ibuzatrelvir [WHO-DD]
- ibuzatrelvir inn
- ibuzatrelvir usan
- ibuzatrelvir who dd
- pf 07817883
- Pf-07817883
- PF-07817883
- CAS registry numbers
- 2755812-39-4
- ChEMBL ID
- CHEMBL5591580
- InChIKey
- WGNWEPPRWQKSKI-AIEDFZFUSA-N
- PubChem compound IDs
- 163362000
- FDA ingredient codes (UNII)
- KZ2X7QH2VT
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- ibuzatrelvir
- Type
- Synthetic organic
- Drug name stem
- -vir
- Condition
- COVID-19
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT05799495
- NCT05884554
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 3
- Polar surface area
- 140.63
- Calculated partition coefficient (ALogP)
- 1.07
- Calculated partition coefficient (XLogP)
- 1.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 34
- Molecular formula
- C21H30F3N5O5
- Monoisotopic mass
- 489.21990356
- Natural product
- No
- Recorded assays
- 114
- Active assays
- 22
Active assay types
- Confirmatory
Distribution coefficient (LogD)
- Median
- 0.9
- Mean
- 0.9
- Minimum
- 0.9
- Maximum
- 0.9
- Unit
- unitless
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Oral bioavailability
- Median
- 25.55
- Mean
- 25.55
- Minimum
- 21.9
- Maximum
- 29.2
- Unit
- %
- Assays
- 2
- Standard deviation
- 5.16188
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Plasma protein binding
- Median
- 0.423
- Mean
- 0.467
- Minimum
- 0.121
- Maximum
- 0.857
- Unit
- fraction unbound
- Assays
- 3
- Standard deviation
- 0.369968
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Fu
Related records
Trials (11)
- A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir
- A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
- A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.
- A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883.
- A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
- A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.
- A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults
- A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy Adults
- A Study to Learn PF-07817883 Blood Levels After Administration of Tablets of Study Drug to Healthy Adult Volunteers
- A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
- A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized
In development for (1)
- COVID-19 Phase 2